Page URL:

Gene therapy could reverse lethal muscle-wasting disease

8 March 2010
Appeared in BioNews 548

A team of researchers based at Ohio State University, USA, have used gene therapy to restore nerve and muscle function and prolong life in mice with a form of spinal muscular atrophy (SMA), a lethal childhood muscle-wasting disorder. Results from the study, published in the journal Nature Biotechnology, were so encouraging that the researchers hope to progress to human trials within two years.

SMA is caused by a fault in a gene known as survival motor neuron 1 (SMN1). The mice in this study were genetically engineered to lack the SMN1 gene so that they developed a condition mimicking human SMA. A modified virus was then used to transport a working version of the SMN1 gene into the cells of the newborn mice. This restarted normal production of the SMN protein, restoring muscle coordination and normal electrical signalling in the muscles. It also dramatically increased the lifespan of the mice allowing them to live over 16 times longer than untreated mice.

The therapy offers a one off treatment to restore the body to normal functioning, giving it an advantage over current experimental drug treatments, which would require a lifetime of medication, according to Professor Arthur Burghes, one of the study's leaders. 'This technique corrects the mice considerably more than any drug cocktails being studied as a potential treatment in humans,' he told the Times.

Infants born with the most severe form of SMA develop paralysis, in some cases becoming so severe they can no longer lift their heads. Children can die before the age of two, often due to respiratory problems. The incurable disease affects up to one in 6000 babies and kills about 50 infants in the UK every year.

Trials on monkeys have shown further promise, but researchers will need to establish it is safe and also determine how early in the patient's life it must be administered, before it can be made available for human use. Furthermore, the symptoms of SMA aren't always apparent at birth, so a newborn screening programme may be necessary to be able to detect the condition early enough for the treatment to work.

Alex MacKenzie, a SMA researcher at the University of Ottawa, Canada, told the Times 'This study combined with the possibility of disease screening in newborns, raises, for the first time, hope of real therapeutic progress against this as yet untreatable disorder'.

Scientists have been cautious about gene therapy since setbacks in early trials, including the death of 18 year old Jesse Gelsinger during a gene therapy trial in 1999. But with safer and more effective approaches now being developed, there is fresh optimism that gene therapy could become a valuable treatment approach for certain single gene disorders, particularly those which are life limiting and have no other treatment options.

Gene therapy for spinal muscular atrophy could be tested in 2 years
TimesOnline |  03/10
Gene therapy may help treat lethal childhood muscle disorder
DNA India |  03/10
Study: Gene therapy reverses effects of lethal childhood muscle disorder in mice |  28 February 2010
25 November 2013 - by Dr Felicity Boardman 
I was struck by a recent article that pushed to free Down's syndrome from inappropriate, negative language - that of 'disease', of 'risk' and of 'defect'...
28 November 2011 - by Suzanne Elvidge 
Researchers have made a step forward in the treatment of spinal muscular atrophy, a serious genetic disorder, by using a stretch of RNA to trigger mice into producing a back-up version of a missing protein...
14 November 2011 - by George Frodsham 
Mice that don't produce a certain protein in their fat cells do not develop type 2 diabetes despite an increase in weight, scientists report. In a separate study, the same research group also managed to double the physical performance of mice by removing the same protein from their muscle cells...
26 September 2011 - by Dr Lux Fatimathas 
An international team of scientists has identified a genetic defect responsible for familial motor neurone disease (MND). A region on chromosome 9 was found to be expanded in 40 percent of people with familial motor neurone disease. It is hoped that a blood test for this disease will be available on the NHS in the near future...
28 March 2011 - by Alison Cranage 
For the first time, gene therapy has shown promise for people with severe Parkinson's disease. Results from a proof of concept clinical trial in the US were published in the journal Lancet Neurology...
15 November 2009 - by Alison Cranage 
Research published in the journal Science Translational Medicine last week shows gene therapy can improve muscle size and strength in monkeys. The technique holds promise as a therapy for several neuromuscular disorders, and researchers hope that clinical trials will start next year....
8 November 2009 - by Dr Rebecca Robey 
Gene therapy has been used to treat two young boys with a devastating and fatal brain disease called adrenoleukodystrophy (ALD). Two years after treatment, both boys showed signs that the disease had stopped progressing and that there were no serious side effects from the gene therapy. These results, published in the journal Science, show huge promise, both for the future treatment of ALD and for the revival of investigations into the use of gene therapy to treat a wide variety ...
2 November 2009 - by Dr Charlotte Maden 
Donor lungs damaged before transplantation can be repaired using a gene therapy technique developed by a team of scientists in Canada. This may increase the supply of functional lungs for transplant patients, by using organs that are currently discarded....
1 November 2009 - by Dr Marianne Kennedy 
US doctors have used gene therapy to restore significant vision in 12 patients who were previously blinded by a disease called Leber's congenital amaurosis. The study, conducted by researchers at the Children`s Hospital of Philadelphia and the University of Pennsylvania School of Medicine, was published online in the Lancet on 24 October....
25 October 2009 - by Dr Marianne Kennedy 
A potential new gene therapy for Duchenne Muscular Dystrophy (DMD) is now set to enter clinical trials after encouraging results in mice. The multinational team of scientists, publishing their findings in the journal Molecular Therapy, demonstrated that the therapy dramatically prevented severe muscle deterioration and extended the lifespan of mice with symptoms of DMD....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.